ENTA vs. ATXS, MBX, PRTC, KMDA, CYRX, TERN, AKBA, ALLO, ABVX, and KOD
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Astria Therapeutics (ATXS), MBX Biosciences (MBX), PureTech Health (PRTC), Kamada (KMDA), Cryoport (CYRX), Terns Pharmaceuticals (TERN), Akebia Therapeutics (AKBA), Allogene Therapeutics (ALLO), ABIVAX Société Anonyme (ABVX), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.
Enanta Pharmaceuticals vs.
Enanta Pharmaceuticals (NASDAQ:ENTA) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Astria Therapeutics. MarketBeat recorded 3 mentions for Enanta Pharmaceuticals and 1 mentions for Astria Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 0.51 beat Astria Therapeutics' score of 0.46 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.
Enanta Pharmaceuticals currently has a consensus target price of $17.25, suggesting a potential upside of 233.01%. Astria Therapeutics has a consensus target price of $25.60, suggesting a potential upside of 241.33%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Astria Therapeutics is more favorable than Enanta Pharmaceuticals.
Astria Therapeutics received 248 more outperform votes than Enanta Pharmaceuticals when rated by MarketBeat users. Likewise, 72.94% of users gave Astria Therapeutics an outperform vote while only 56.99% of users gave Enanta Pharmaceuticals an outperform vote.
Astria Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Astria Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 13.6% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Astria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Enanta Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
Astria Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -171.57%. Astria Therapeutics' return on equity of -43.58% beat Enanta Pharmaceuticals' return on equity.
Summary
Astria Therapeutics beats Enanta Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ENTA) was last updated on 1/22/2025 by MarketBeat.com Staff
